Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasudil in early Parkinson's disease
NCT05931575Phase 2Completed
- Sponsor
- Technical University of Munich
- Start
- Sep 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fasudil in Parkinson's disease (PD) (3 arms), sponsored by Technical University of Munich. Primary endpoint: Combined occurrence of intolerance and/or occurrence of self-reported and pre-defined treatment-related SAEs at 22 days. Started Sep 2023; status: completed.
02
Drugs
fasudil
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05931575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05931575.